Comprehensive evaluation of microneedle‐based intradermal adalimumab delivery <i>vs</i>. subcutaneous administration: results of a randomized controlled clinical trial

Abstract

Intradermal injection of adalimumab using hollowing microneedles was perceived as more painful and less accepted than s.c. administration, but yields a higher relative bioavailability with similar safety and pharmacodynamic effects.